Please go to the PowerPak homepage
and select a course.
Novel Mechanisms in the Management of Acute Myeloid Leukemia: A 2018 Update for Pharmacists
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Pfizer.
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Departments of Hematology/Medical Oncology and Pharmacology
Emory University School of Medicine
Dr. Harvey has disclosed that he has served as a consultant for Genentech and Takeda; and that his institution has received research funding from Abbvie, Amgen, Astra Zeneca, Boston Biomedical, Bristol-Meyers Squibb, Five Prime Therapeutics, GenMab, Halozyme, Medimmune, Merck, Novartis, Pfizer, Regeneron, Syndax, Seattle Genetics, Takeda and Tesaro that supports his salary.
The clinical reviewer, Megan May, PharmD, BCOP, has no actual or potential conflict of interest in relation to this program.
Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN-RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.0 hour (0.1 ceu)
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes
August 24, 2018
August 24, 2019
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period August 24, 2018 through August 24, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To inform oncology, managed care and specialty pharmacists, as well as other pharmacists who interact with Acute Myeloid Leukemia (AML) patients, on (1) novel and emerging therapeutic options in AML and their mechanisms of action (2) the efficacy and safety of current and emerging treatment considerations for AML; (3) approaches to recognize AML patients who are likely to benefit from newly approved therapeutic options or novel targeted agents; and (4) pharmacist driven strategies to manage patients' adherence and unique adverse events when utilizing oral chemotherapy agents thus leading to improved outcomes.
Upon completion of this program, participants should be better able to:
- Review the epidemiology, pathophysiology and traditional approaches for the management of acute myeloid leukemia (AML)
- Discuss the indications, efficacy, safety and mechanism of action of medications recently approved for the management of patients with AML
- Describe the pivotal clinical trial data considered by the FDA during review in order to recognize AML patients who are likely to benefit from novel therapies
- Identify the signs and symptoms of adverse effects of these agents and choose appropriate management strategies
*Click here to Download: Point of Care Reference Tool (PDF)
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
DISCLOSURE OF UNLABELED USE AND DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Pfizer. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.